Biology Reference
In-Depth Information
[70] Durie FH, Aruffo A, Ledbetter J, Crassi KM, Green WR, Fast LD, et al. Antibody to the
ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-
vs-host disease. J Clin Invest 1994;94:1333-8.
[71] Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell RA, et al. Blockade
of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhib-
iting mature donor T cell expansion and function after bone marrow transplantation.
J Immunol 1997;158:29-39.
[72] Hargreaves RE, Monk NJ, Jurcevic S. Selective depletion of activated T cells: the CD40L-
specific antibody experience. Trends Mol Med 2004;10:130-5.
[73] Verbinnen B, Billiau AD, Vermeiren J, Galicia G, Bullens DM, Boon L, et al. Contribution
of regulatory T cells and effector T cell deletion in tolerance induction by costimulation
blockade. J Immunol 2008;181:1034-42.
[74] Kim J, Park K, Kim HJ, Kim HA, Jung D, Choi HJ, et al. Breaking of CD8+ T cell toler-
ance through in vivo ligation of CD40 results in inhibition of chronic graft-versus-host
disease and complete donor cell engraftment. J Immunol 2008;181:7380-9.
[75] Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface
of tolerance and immunity. Annu Rev Immunol 2004;22:307-28.
[76] Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications
after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6:114.
[77] Xu H, Zhang X, Mannon RB, Kirk AD. Platelet-derived or soluble CD154 induces
vascularized allograft rejection independent of cell-bound CD154. J Clin Invest
2006;116:769-74.
[78] Adams AB, Shirasugi N, Jones TR, Durham MM, Strobert EA, Cowan S, et al. Develop-
ment of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to
prolong islet allograft survival. J Immunol 2005;174:542-50.
[79] Saito K, Sakurai J, Ohata J, Kohsaka T, Hashimoto H, Okumura K, et al. Involvement of
CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease
induced by allogeneic T cells lacking CD28. J Immunol 1998;160:4225-31.
[80] Miller WP, Srinivasan S, Panoskaltsis-Mortari A, Singh K, Sen S, Hamby K, et al. GVHD after
haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies
CD28− CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimula-
tion blockade and sirolimus-based immunosuppression. Blood 2010;116:5403-18.
[81] Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology
and immune disease. Immunol Rev 2009;229:173-91.
[82] Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory
molecule for sustaining primary CD4 T cell responses. J Immunol 1998;161:6510-7.
[83] Lane P. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cyto-
kine differentiation in T helper (Th)1 and Th2 cells. J Exp Med 2000;191:201-6.
[84] Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-
stimulatory molecule OX40. Nat Rev Immunol 2004;4:420-31.
[85] Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT. Expression of the T-cell activation
antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood
1997;89:4652-8.
[86] Sanchez J, Casano J, Alvarez MA, Roman-Gomez J, Martin C, Martinez F, et al. Kinetic
of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and
chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Br J Haematol 2004;126:697-703.
[87] Blazar BR, Sharpe AH, Chen AI, Panoskaltsis-Mortari A, Lees C, Akiba H, et al. Ligation
of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in
allogeneic bone marrow transplant recipients. Blood 2003;101:3741-8.
[88] Ge X, Brown J, Sykes M, Boussiotis VA. CD134-allodepletion allows selective elimina-
tion of alloreactive human T cells without loss of virus-specific and leukemia-specific
effectors. Biol Blood Marrow Transplant 2008;14:518-30.
[89] Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL:
complexities and challenges. Immunol Rev 2009;229:192-215.
[90] Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, et al. 4-1BB
ligand induces cell division, sustains survival, and enhances effector function of CD4
and CD8 T cells with similar efficacy. J Immunol 2001;167:1313-24.
[91] Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA. Liga-
tion of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia,
and graft rejection in allogeneic bone marrow transplant recipients. J Immunol
2001;166:3174-83.
[92] Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, et al. 4-1BB
costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the
amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47-55.
218
Search WWH ::
Custom Search